BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Biotechnology Industry Organization (BIO) CEOs To Testify On IRS Stock Option Regulations


1/23/2006 1:01:23 PM

WASHINGTON, Jan. 23 /PRNewswire/ -- Gary McGarrity, president and CEO of Intronn, and Lawrence Tamarkin, president and CEO of CytImmune Sciences Inc., will testify on behalf of the Biotechnology Industry Organization (BIO) Wednesday on proposed regulations pertaining to the Internal Revenue Code (IRC) Section 409A.

Approved by Congress in 2004 as part of the American Jobs Act, IRC Section 409A imposes income tax liability and penalties on company employees who presumably receive below fair market value stock options. The law takes effect Jan. 1, 2007.

BIO has raised concerns about ambiguity regarding the Internal Revenue Services' (IRS) proposed methodology for determining the value of stock options, especially for private companies, according to Morrie Ruffin, BIO's executive vice president of capital formation and business development.

"If the proposed regulations are not further clarified and implemented appropriately, it will hinder the entrepreneurial spirit of the best and the brightest talents who could be working toward a cure for many of the ailments facing Americans today," Ruffin said.

The IRS and the U.S. Department of Treasury are accepting stakeholder comments on pending regulations associated with law. As part of the comment process, the IRS and treasury department will hold a public hearing at 10 a.m. Wednesday, Jan. 25 at the IRS building located at 1111 Constitution Ave. NW, Washington DC, Room 7218. McGarrity and Tamarkin are expected to testify between 11:30 a.m. and 1:30 p.m.

In comments recently submitted to the IRS, BIO suggests that company management or boards of directors are in the best position to assess the value of stock options in good faith. The valuation should be honored by the IRS unless the assessments were done in bad faith.

BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products.

Biotechnology Industry Organization

CONTACT: Kim Coghill of the Biotechnology Industry Organization,+1-202-962-9200


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->